Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brandon M Huffman

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
JCO Precision Oncology|December 8, 2022
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric CancersBrandon M Huffman, Vasily N Aushev, Griffin L Budde, et al.
NPJ Precision Oncology|May 6, 2024
Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targetingAurel Prosz, Pranshu Sahgal, Brandon M Huffman, et al.
NPJ Precision Oncology|April 8, 2024
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targetingAurel Prosz, Pranshu Sahgal, Brandon M Huffman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2024
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic CancerHarshabad Singh, Joanne Xiu, Kevin S Kapner, et al.
Cancer Immunology Research|September 30, 2024
A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal CancerBrandon M Huffman, Osama E Rahma, Kevin Tyan, et al.
JCO Precision Oncology|June 21, 2023
Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI CancerHarshabad Singh, Samuel J Klempner, Nelya Melnitchouk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2023
A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic AdenocarcinomaBrandon M Huffman, Hanrong Feng, Kalindi Parmar, et al.
Cancer Cell|May 8, 2026
Dendritic cell redundancy enables priming of anti-tumor CD4<sup>+</sup> T cells in pancreatic cancerCourtney T S Kureshi, Michael J Walsh, Rakeeb Kureshi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2026
A Phase 2 Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2Brandon M Huffman, Miklos Diossy, Matthew B Yurgelun, et al.
Journal for Immunotherapy of Cancer|January 25, 2024
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term respondersBrandon M Huffman, Harshabad Singh, Lestat R Ali, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
JCO Precision Oncology|December 8, 2022
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric CancersBrandon M Huffman, Vasily N Aushev, Griffin L Budde, et al.
NPJ Precision Oncology|May 6, 2024
Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targetingAurel Prosz, Pranshu Sahgal, Brandon M Huffman, et al.
NPJ Precision Oncology|April 8, 2024
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targetingAurel Prosz, Pranshu Sahgal, Brandon M Huffman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2024
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic CancerHarshabad Singh, Joanne Xiu, Kevin S Kapner, et al.
Cancer Immunology Research|September 30, 2024
A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal CancerBrandon M Huffman, Osama E Rahma, Kevin Tyan, et al.
JCO Precision Oncology|June 21, 2023
Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI CancerHarshabad Singh, Samuel J Klempner, Nelya Melnitchouk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2023
A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic AdenocarcinomaBrandon M Huffman, Hanrong Feng, Kalindi Parmar, et al.
Cancer Cell|May 8, 2026
Dendritic cell redundancy enables priming of anti-tumor CD4<sup>+</sup> T cells in pancreatic cancerCourtney T S Kureshi, Michael J Walsh, Rakeeb Kureshi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2026
A Phase 2 Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2Brandon M Huffman, Miklos Diossy, Matthew B Yurgelun, et al.
Journal for Immunotherapy of Cancer|January 25, 2024
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term respondersBrandon M Huffman, Harshabad Singh, Lestat R Ali, et al.
Pageof 4